# SKB264-Ⅱ-08: what clinicians are saying

> 62 statements from 10 sources (8 posts, 2 papers), 21 of them from 7 confirmed clinicians, each linked to its source. Commentary checked Nov 19, 2026.

## Report

- Trial: A Multicenter, Open-label, Phase 2 Study to Evaluate the Efficacy and Safety of SKB264 Monotherapy in Selected Subjects With Advanced Solid Tumors
- NCT ID: NCT05631262
- Registry: https://clinicaltrials.gov/study/NCT05631262
- Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
- Phase: Phase 2
- Status: Active, not recruiting
- Drugs tested: sacituzumab tirumotecan
- Indication: advanced solid tumors
- Version: v1.0.0, edition 1
- Accepted: 2026-11-19 UTC
- Last checked: 2026-11-19 UTC
- Release hash: ec8465801654378542bd8a6e6a7938f24359b2536ff4ee8000c655e82e0557ef

## Counts

- Commentary sources screened: 19
- Sources cited by verified statements: 10
- Verified statements: 62
- From speakers with a confirmed clinical role (verified by the NPI registry or their own institution's staff page): 21
- Findings: 8
- Named people in screened sources (unnamed speakers and accounts not counted): 9
- Speakers cited: 9
- Cited speakers with a verified identity: 8
- Cited clinicians, speakers with a confirmed clinical role (the abstract's clinicians): 7
- Of them physicians, whose confirmed role is a physician's, not a physician assistant's, nurse's or pharmacist's (the abstract's physicians): 7
- By role and specialty (the abstract's specialty counts):
  - 4 physician, Medical oncology
  - 3 physician, specialty not confirmed
- Organisational or shared accounts (not counted as people): 1

A verified identity says who a speaker is. A cited clinician also has a clinical role confirmed by the NPI registry or their own institution's staff page. Verified speakers without such a role, such as researchers, advocates, company staff, or clinicians whose role only a source or their own profile states, are not counted as clinicians.

Counts describe the retained sources. They do not estimate how many HCPs hold a view.

## Abstract

Some cited clinicians read SKB264-Ⅱ-08 favorably for tumour-response gains, while a medical oncologist rejects its characterization as registrational, citing docetaxel’s performance. A different medical oncologist combines a favorable benefit–risk reading with questions about prioritizing tumour response. Their interpretation remains qualified by immature survival data and a call for evidence beyond China.

## Question clinicians left open

What do clinicians say would resolve concerns about OptiTROP-Lung03’s ORR primary endpoint and PFS reliability for sac-TMT versus docetaxel in advanced EGFR-mutated NSCLC after EGFR-TKI and platinum chemotherapy?

From finding F1 (15 statements from 4 speakers in 4 sources). The report shows what clinicians said and the sources behind it; it does not settle the question.

## Findings (titles)

- F1. Primary ORR: some clinicians question it; some doubt registrational framing
  - 15 statements from 4 speakers in 4 sources.
  - 2 of the 4 named speakers in this finding hold this view, each a confirmed clinician; 2 of the 4 hold its caveat, “some doubt registrational framing”.
  - 4 of the report's 7 cited clinicians.
- F2. Sacituzumab tirumotecan: where clinicians split on confidence in its benefit
  - 11 statements from 5 speakers in 5 sources.
  - 5 of the 5 named speakers in this finding take a side on this question: 3 on one side, 2 on the other; every named speaker in this finding is a confirmed clinician.
  - 5 of the report's 7 cited clinicians.
- F3. OS interpretation: a clinician stresses immaturity and crossover despite ORR/PFS gains
  - 8 statements from 2 speakers in 4 sources.
  - 1 of the 2 named speakers in this finding holds this view, a confirmed clinician; 2 of the 2 hold its caveat, “despite ORR/PFS gains”.
  - 2 of the report's 7 cited clinicians.
- F4. Safety: a clinician notes fewer grade ≥3 AEs; most flag specific toxicities
  - 13 statements from 3 speakers in 4 sources.
  - 1 of the 3 named speakers in this finding holds this view, a confirmed clinician; 2 of the 3 hold its caveat, “most flag specific toxicities”.
  - 3 of the report's 7 cited clinicians.
- F5. TROP2 IHC: where clinicians split on its predictive role
  - 3 statements from 2 speakers in 3 sources.
  - 2 of the 2 named speakers in this finding take a side on this question: 1 on one side, 1 on the other; every named speaker in this finding is a confirmed clinician.
  - 2 of the report's 7 cited clinicians.
- F6. Sacituzumab tirumotecan: a clinician calls for global data despite its China licence
  - 4 statements from 1 speaker in 2 sources.
  - The one named speaker in this finding holds this view, a confirmed clinician; 1 of them holds its caveat, “despite its China licence”.
  - 1 of the report's 7 cited clinicians.
- F7. Spain: a speaker notes delays; a clinician tentatively suggests trials
  - 2 statements from 2 speakers in 1 source.
  - 1 of the 2 named speakers in this finding holds this view; 1 of the 2 holds its caveat, “a clinician tentatively suggests trials”.
  - 1 of the report's 7 cited clinicians.
- F8. Activity range: what speakers see; a clinician flags small N and scant CNS data
  - 6 statements from 2 speakers in 3 sources.
  - 2 of the 2 named speakers in this finding hold this view; 1 of them holds its caveat, “a clinician flags small N and scant CNS data”.
  - 1 of the report's 7 cited clinicians.

## What sits behind each finding

Counts describe what the report retained, not how many clinicians hold a view. A statement can support more than one finding. Speakers are the named people a finding's statements cite, of any role, counted as the report counts its cited speakers; unnamed speakers and accounts are not counted.

| Finding | Statements | Passages | Sources | Speakers | Limitations |
| --- | ---: | ---: | ---: | ---: | ---: |
| F1 | 15 | 8 | 4 | 4 | 3 |
| F2 | 11 | 7 | 5 | 5 | 3 |
| F3 | 8 | 8 | 4 | 2 | 3 |
| F4 | 13 | 7 | 4 | 3 | 4 |
| F5 | 3 | 3 | 3 | 2 | 2 |
| F6 | 4 | 2 | 2 | 1 | 2 |
| F7 | 2 | 2 | 1 | 2 | 2 |
| F8 | 6 | 4 | 3 | 2 | 4 |

### What the statements are

| Finding | Views | Questions and uncertainty | Clinical experience | Comparisons | Restated results and context | Statement links to supporting passages | Statement links to context passages | Sources by kind |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | --- |
| F1 | 8 | 4 | 0 | 0 | 3 | 16 | 0 | 3 posts and articles, 1 publication |
| F2 | 5 | 3 | 0 | 2 | 1 | 12 | 2 | 4 posts and articles, 1 publication |
| F3 | 2 | 0 | 0 | 1 | 5 | 9 | 0 | 3 posts and articles, 1 publication |
| F4 | 6 | 0 | 0 | 3 | 4 | 14 | 0 | 3 posts and articles, 1 publication |
| F5 | 1 | 1 | 0 | 0 | 1 | 3 | 1 | 2 posts and articles, 1 publication |
| F6 | 3 | 0 | 0 | 1 | 0 | 4 | 0 | 1 post or article, 1 publication |
| F7 | 1 | 1 | 0 | 0 | 0 | 2 | 0 | 1 post or article |
| F8 | 3 | 1 | 0 | 0 | 2 | 7 | 0 | 2 posts and articles, 1 publication |

### Trial dimensions

- Primary endpoint: Objective Response Rate (ORR): F1 (4 shared claims), F2 (5 shared claims), F3 (4 shared claims), F4 (3 shared claims), F6 (1 shared claims)
- Primary endpoint: Incidence and severity of adverse events (AEs): F1 (2 shared claims), F2 (2 shared claims), F3 (2 shared claims), F4 (5 shared claims), F6 (1 shared claims)
- Secondary endpoints: F1 (4 shared claims), F2 (5 shared claims), F3 (4 shared claims), F4 (3 shared claims), F6 (1 shared claims)
- Population and setting: F1 (3 shared claims), F2 (5 shared claims), F3 (3 shared claims), F4 (3 shared claims), F6 (2 shared claims)
- The comparison: F1 (4 shared claims), F2 (4 shared claims), F3 (4 shared claims), F4 (5 shared claims), F6 (1 shared claims)
- Safety and tolerability: F1 (2 shared claims), F2 (2 shared claims), F3 (2 shared claims), F4 (5 shared claims), F6 (1 shared claims)
- Design and conduct: F1 (9 shared claims), F2 (3 shared claims), F3 (2 shared claims), F4 (2 shared claims)

## Abbreviations

- ADC: antibody–drug conjugate
- AE: adverse event
- CNS: central nervous system
- EGFR: epidermal growth factor receptor
- HCP: healthcare professional
- MCP: Model Context Protocol, how AI agents read the report
- NPI: National Provider Identifier, the US registry number for clinicians
- NSCLC: non-small cell lung cancer
- ORR: objective response rate
- OS: overall survival
- PFS: progression-free survival

## What's inside

| Section | Items | Access |
| --- | ---: | --- |
| Findings with interpretation, counterviews and limits | 8 | Titles free |
| Detailed analysis | 9 sections | Paid |
| Verified statements with short source quotes and links | 62 | Paid |
| Who said each statement: the cited speakers | 9 | Every edition |
| Speakers with a clinical role confirmed by the NPI registry or a staff page | 7 | Every edition |
| Speakers with verified IDs as data (NPI, ORCID, staff page) | 8 | Every edition |
| CMS-reported financial relationships (Open Payments, by company) for NPI-linked speakers | Included | Every edition |
| Trial aspects mapped | 12 | Free |
| Sources with links | 10 | Counts free |
| MCP access for your AI agent, same license key | Included | Every edition |

Every edition, the free report included, names who said each statement, as the source shows them. Each named speaker's card gives a clinical role only when the NPI registry or the person's own institution's staff page confirms it, and says which; a role only a source states is labelled as the source's. Here 7 of the 9 cited speakers have a role confirmed that way. Every edition also comes with MCP access, so your AI agent reads the same evidence with your license key, and with verified IDs for each identity-checked speaker (the NPI, ORCID and OpenAlex IDs, and their institution's staff page), so your team can check each attribution itself. Social accounts are not included. The IDs are for checking attribution inside your organization. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians.

## Trial aspects

12 discussed · 0 no commentary found · 0 assessment incomplete.

| Aspect | Coverage | Statements | Sources |
| --- | --- | ---: | ---: |
| Primary endpoint: Objective Response Rate (ORR) | discussed | 9 | 6 |
| Primary endpoint: Incidence and severity of adverse events (AEs) | discussed | 5 | 3 |
| Secondary endpoints | discussed | 8 | 5 |
| Population and setting | discussed | 8 | 6 |
| The comparison (The registered arms and what clinicians said about how they compare.) | discussed | 9 | 5 |
| Safety and tolerability | discussed | 5 | 3 |
| Design and conduct | discussed | 9 | 3 |
| TROP2 IHC, selection and development-program expectations | discussed | 2 | 2 |
| Global applicability and reported Chinese licensing | discussed | 1 | 1 |
| Spanish access and possible research participation | discussed | 2 | 1 |
| Whether benefit will hold in light of experience with other TROP2 ADCs | discussed | 1 | 1 |
| Broader actionable-alteration cohorts, CNS evidence and next-study expectations | discussed | 5 | 2 |

Discussed means at least one verified statement addresses the aspect, not that every question in it is covered: gaps inside a discussed aspect are listed under Scope and limits, and the full report gives each aspect its own limitations. No commentary found means none in the sources read. Assessment incomplete marks an aspect with no statement found while known source limits apply.

## Sources

| Channel | Statements | Cited | Screened |
| --- | ---: | ---: | ---: |
| **Posts · 26 statements · 42%** | | | |
| X threads | 26 | 8 | 16 |
| Bluesky threads | 0 | 0 | 3 |
| **Primary sources · 36 statements · 58%** (cited for context, not screened) | | | |
| Publications (primary source, cited for context) | 36 | 2 | not screened |

- Screened window: 2025-04-13 to 2026-09-14
- Cited window: 2025-06-01 to 2026-09-14
- Retrieved: 2026-11-19

Statements count each verified statement once, split evenly over the sources it cites. Screened sources were retrieved for this trial. Cited sources back at least one verified statement and include primary sources used for context.

## The trial

From ClinicalTrials.gov.

- Title: A Multicenter, Open-label, Phase 2 Study to Evaluate the Efficacy and Safety of SKB264 Monotherapy in Selected Subjects With Advanced Solid Tumors
- Registry: NCT05631262 (https://clinicaltrials.gov/study/NCT05631262)
- Study IDs: SKB264-Ⅱ-08
- Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
- Design: Phase 2 · interventional, randomized, parallel, phase2
- Status: Active, not recruiting
- Enrollment: 321 (actual)
- Start: 2022-11-30 (actual)
- Primary completion: 2026-12-30 (estimated)
- Primary endpoint: Objective Response Rate (ORR) (From baseline until disease progression, death, or other protocol defined reason, up to approximately 21 months.)
- Primary endpoint: Incidence and severity of adverse events (AEs) (From subject sign the informed consent form (ICF) to 30 days after the last dose of study treatment.)
- Intervention: SKB264 (drug)
- Intervention: Docetaxel (drug)

## Scope and limits

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

- Discussion that does not name the trial may be missing from this edition.
- 10 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
- Further source limits: 52 sources about other trials or topics are not included.
- Discussion may be missing when a source used an unnamed reference, a different spelling or another way of describing the study. The report should not be read as exhaustive public sentiment.
- Public X reactions, presenter relays and publication summaries do not establish independent clinician counts, consensus, prescribing behavior or patient outcomes in routine care.
- A separate protocol and an exact SKB264 regulatory label were not available among the documents reviewed. Regulatory-endpoint and licensing statements therefore remain attributed accounts rather than independently confirmed requirements or indications.
- Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.
- The June 2025 randomized-comparison discussion and the September 2026 molecularly broader posts address different settings. Post dates and meeting hashtags do not establish session dates or changes in opinion.
- Some reported descriptions differ, including phase 2 versus phase 3 labeling and OS hazard ratios. The report preserves those differences rather than creating a reconciled estimate.

How reports are built and checked: https://www.erudio.com/methods

## Editions and corrections

- v1.0.0, edition 1, accepted 2026-11-19 UTC: current edition

Each new edition gets a new version: a new or changed finding raises the middle number (1.0.0 to 1.1.0), added evidence or newly verified speakers alone the last number (1.0.0 to 1.0.1), and a change of report format the first number. A correction fixes the published edition in place without making a new edition, so the version stays the same. Changes are corrections that add, remove or change a statement or finding, or withdraw a source; routine maintenance (people cards, names and spellings, recounts, tags and page wording) changes none. Every correction is listed here with its date. Last checked for new commentary 2026-11-19 UTC. No changes.

## Offer

- Size: Focused · 62 verified statements · 21 from 7 confirmed clinicians
- Current edition: $750. A purchase starts a check for new commentary and any newer edition follows at no charge
- 3 months of updates: $1,300
- 6 months of updates: $1,900
- 12 months of updates: $2,600
- Every product includes verified IDs for each identity-checked speaker (the NPI, ORCID and OpenAlex IDs, and their institution's staff page), so your team can check each attribution itself (8 identity-verified speakers now); social accounts are not included. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians.
- Pricing: https://www.erudio.com/pricing
- Buy now (card, through Stripe): https://www.erudio.com/reports/skb264-08-nct05631262
- Agents: POST https://www.erudio.com/api/orders with {"report": "skb264-08-nct05631262", "product": "edition" | "updates-3" | "updates-6" | "updates-12", "buyer_email": "...", "organization": "...", "licence_key": "<your key, if you hold one>"}; it returns a payment link for your user and a pay_url your own payment client can pay over HTTP 402 in USDC, with MPP (on Tempo) or x402 (on Base), and once paid the status_url returns your license key. Send the same key with every later order so all reports sit on one key. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST https://www.erudio.com/api/keys/recover) sends it again
- Talk to Audun Utengen and Tom Lee (invoice, PO, questions): https://www.erudio.com/contact?report=skb264-08-nct05631262

## Cite

Erudio Health. SKB264-Ⅱ-08 (NCT05631262): HCP commentary report. Edition 1, v1.0.0. Accepted Nov 19, 2026. https://www.erudio.com/reports/skb264-08-nct05631262

## Questions

### How much does the SKB264-Ⅱ-08 report cost?

One edition costs $750 (Focused · 62 verified statements · 21 from 7 confirmed clinicians). With updates: 3 months $1,300, 6 months $1,900, 12 months $2,600. Subscriptions are prepaid, and the price is fixed for the term you buy, even if a new edition moves the trial up a size. Nothing renews automatically: a new term is bought at the price then current.

### What does the SKB264-Ⅱ-08 report cover?

62 statements from 10 sources (8 posts, 2 papers), 21 of them from 7 confirmed clinicians, each linked to its source. Commentary checked Nov 19, 2026. The report separates what clinicians said from what primary sources establish; it does not judge efficacy or estimate consensus.

### Can my AI agent read or buy the SKB264-Ⅱ-08 report?

Yes. On https://mcp.erudio.com/free, with no sign-in, get_report_card({ "slug": "skb264-08-nct05631262" }) previews it and create_order({ "report": "skb264-08-nct05631262", "product": "edition", "buyer_email": "<work email>" }) orders it. Once paid, the license key reads it with read_report on https://mcp.erudio.com/mcp. [Connect your AI client](https://www.erudio.com/developers/connect)

### How current is the SKB264-Ⅱ-08 report?

Edition 1 (version 1.0.0), accepted Nov 19, 2026 UTC; last checked for new commentary Nov 19, 2026 UTC. Your plan includes every new edition published during its term. We automatically check subscribed trials for new commentary every week.

## Machine access

- JSON: https://www.erudio.com/reports/skb264-08-nct05631262.json
- Markdown: https://www.erudio.com/reports/skb264-08-nct05631262.md
- Change feed (JSON Feed: new editions and changes): https://www.erudio.com/reports/skb264-08-nct05631262/feed.json
- MCP, no sign-in: https://mcp.erudio.com/free, tool `get_report_card` with `{"slug": "skb264-08-nct05631262"}`
